{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:25:58Z","timestamp":1791941158145,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We conducted a nationwide, registry-based study to investigate the importance of 34 potential risk factors for coronavirus disease 2019 (COVID-19) diagnosis, hospitalization (with or without intensive care unit [ICU] admission), and subsequent all-cause mortality. The study population comprised all COVID-19 cases confirmed in Sweden by mid-September 2020 (68,575 non-hospitalized, 2494 ICU hospitalized, and 13,589 non-ICU hospitalized) and 434,081 randomly sampled general-population controls. Older age was the strongest risk factor for hospitalization, although the odds of ICU hospitalization decreased after 60\u201369\u00a0years and, after controlling for other risk factors, the odds of non-ICU hospitalization showed no trend after 40\u201349\u00a0years. Residence in a long-term care facility was associated with non-ICU hospitalization. Male sex and the presence of at least one investigated comorbidity or prescription medication were associated with both ICU and non-ICU hospitalization. Three comorbidities associated with both ICU and non-ICU hospitalization were asthma, hypertension, and Down syndrome. History of cancer was not associated with COVID-19 hospitalization, but cancer in the past year was associated with non-ICU hospitalization, after controlling for other risk factors. Cardiovascular disease was weakly associated with non-ICU hospitalization for COVID-19, but not with ICU hospitalization, after adjustment for other risk factors. Excess mortality was observed in both hospitalized and non-hospitalized COVID-19 cases. These results confirm that severe COVID-19 is related to age, sex, and comorbidity in general. The study provides new evidence that hypertension, asthma, Down syndrome, and residence in a long-term care facility are associated with severe COVID-19.<\/jats:p>","DOI":"10.1007\/s10654-021-00732-w","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:02:55Z","timestamp":1615438975000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-6140","authenticated-orcid":false,"given":"Jonathan","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-7208","authenticated-orcid":false,"given":"Marcel","family":"Ballin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-456X","authenticated-orcid":false,"given":"Anna","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-508X","authenticated-orcid":false,"given":"Peter","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"732_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jama.2020.1097","volume":"323","author":"AL Phelan","year":"2020","unstructured":"Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709\u201310.","journal-title":"JAMA"},{"key":"732_CR2","unstructured":"World Health Organization. Listings of WHO\u2019s response to COVID-19. https:\/\/www.who.int\/news\/item\/29-06-2020-covidtimeline. Accessed 21 Dec 2020."},{"key":"732_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1126\/science.abb6105","volume":"368","author":"H Tian","year":"2020","unstructured":"Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science. 2020;368:638\u201342.","journal-title":"Science"},{"key":"732_CR4","doi-asserted-by":"publisher","first-page":"m1985","DOI":"10.1136\/bmj.m1985","volume":"369","author":"AB Docherty","year":"2020","unstructured":"Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.","journal-title":"BMJ"},{"key":"732_CR5","first-page":"16","volume":"2","author":"L Kim","year":"2020","unstructured":"Kim L, Garg S, O\u2019Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2020;2:16.","journal-title":"Clin Infect Dis"},{"key":"732_CR6","doi-asserted-by":"publisher","first-page":"m1966","DOI":"10.1136\/bmj.m1966","volume":"369","author":"CM Petrilli","year":"2020","unstructured":"Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.","journal-title":"BMJ"},{"key":"732_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136.","journal-title":"Nature"},{"key":"732_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/ije\/dyaa140","volume":"49","author":"M Reilev","year":"2020","unstructured":"Reilev M, Kristensen KB, Potteg\u00e5rd A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468\u201381.","journal-title":"Int J Epidemiol"},{"key":"732_CR9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763\u201370.","journal-title":"Lancet"},{"key":"732_CR10","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"732_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324:168\u201377.","journal-title":"JAMA"},{"key":"732_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","volume":"8","author":"E Barron","year":"2020","unstructured":"Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813\u201322.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"732_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765\u201373.","journal-title":"Eur J Epidemiol"},{"key":"732_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"key":"732_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol (Madr). 2009;48:27\u201333.","journal-title":"Acta Oncol (Madr)"},{"key":"732_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, MichaelFored C, et al. The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"732_CR17","unstructured":"Kroksg\u00e5rd A. Kvalitetsdeklaration-statistik om socialtj\u00e4nstinsatser till \u00e4ldre 2019. Stockholm [SE]: Socialstyrelsen; 2020. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2020-4-6745-kvalitetsdeklaration.pdf"},{"key":"732_CR18","unstructured":"Svenska Intesivv\u00e5rdsregistret. Svenska Intesivv\u00e5rdsregistret \u00c5rsrapport 2019. 2020. https:\/\/www.icuregswe.org\/globalassets\/arsrapporter\/arsrapport_2019_final.pdf"},{"key":"732_CR19","unstructured":"Statistiska centralbyr\u00e5n. Befolkning efter \u00e5lder och k\u00f6n. \u00c5r 1860\u20132019. https:\/\/www.statistikdatabasen.scb.se\/pxweb\/sv\/ssd\/START__BE__BE0101__BE0101A\/BefolkningR1860\/#. Accessed 27 Nov 2020."},{"key":"732_CR20","first-page":"20","volume":"21","author":"A Clift","year":"2020","unstructured":"Clift A, Coupland C, Keogh R, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2020;21:20\u20134986.","journal-title":"Ann Intern Med"},{"key":"732_CR21","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, et al. Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"732_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020\u20136.","journal-title":"JAMA Cardiol"},{"issue":"20","key":"732_CR23","first-page":"30558","volume":"S2213\u20132600","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin\u2013angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;S2213\u20132600(20):30558.","journal-title":"Lancet Respir Med"},{"key":"732_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros E, Silva PGM, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254\u201364.","journal-title":"JAMA"},{"key":"732_CR25","doi-asserted-by":"publisher","first-page":"e23327","DOI":"10.1097\/MD.0000000000023327","volume":"99","author":"Z Wang","year":"2020","unstructured":"Wang Z, Deng H, Ou C, et al. Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19: a systematic review and meta-analysis without cases duplication. Medicine (Baltimore). 2020;99:e23327.","journal-title":"Medicine (Baltimore)"},{"key":"732_CR26","first-page":"1","volume":"5","author":"S Bae","year":"2020","unstructured":"Bae S, Kim SR, Kim M-N, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2020;5:1\u20138.","journal-title":"Heart"},{"key":"732_CR27","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.jinf.2020.04.021","volume":"81","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16-25.","journal-title":"J Infect"},{"key":"732_CR28","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S0140-6736(20)31199-5","volume":"395","author":"T Burki","year":"2020","unstructured":"Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020;395:1602.","journal-title":"Lancet"},{"key":"732_CR29","unstructured":"Folkh\u00e4lsomyndigheten. Uppdrag f\u00f6r ut\u00f6kad diagnostik av covid-19. https:\/\/www.folkhalsomyndigheten.se\/nyheter-och-press\/nyhetsarkiv\/2020\/mars\/uppdrag-for-utokad-diagnostik-av-covid-19\/. Accessed 21 Dec 2020."},{"key":"732_CR30","unstructured":"Folkh\u00e4lsomyndigheten. Nationell strategi f\u00f6r att ut\u00f6ka provtagningen f\u00f6r covid-19. https:\/\/www.folkhalsomyndigheten.se\/nyheter-och-press\/nyhetsarkiv\/2020\/april\/nationell-strategi-for-att-utoka-provtagningen-for-covid-19\/. Accessed 21 Dec 2020."},{"key":"732_CR31","unstructured":"Regeringen. Regeringen satsar 5,9 miljarder p\u00e5 ut\u00f6kad testning och smittsp\u00e5rning. https:\/\/www.regeringen.se\/pressmeddelanden\/2020\/06\/regeringen-satsar-59-miljarder-pa-utokad-testning-och-smittsparning\/. Accessed 21 Dec 2020."}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-021-00732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10654-021-00732-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-021-00732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T02:05:25Z","timestamp":1617933925000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10654-021-00732-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1007\/s10654-021-00732-w","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Statistical code may be obtained from JB upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was approved by the Swedish Ethical Review Authority, which waived the requirement of obtaining informed consent (Number 2020-02552).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}